for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ArQule, Inc.

ARQL.OQ

Latest Trade

7.89USD

Change

0.00(0.00%)

Volume

437,431

Today's Range

7.67

 - 

7.97

52 Week Range

2.23

 - 

12.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

ArQule Reports Q3 Loss Per Share $0.09

Oct 30 (Reuters) - ArQule Inc <ARQL.O>::ARQULE REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.09.SEES FY 2019 REVENUE $2.0 MILLION TO $5.0 MILLION.Q3 REVENUE $200,000 VERSUS $5.0 MILLION.Q3 REVENUE ESTIMATE $1.2 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.09 -- REFINITIV IBES DATA.SEES FY 2019 LOSS PER SHARE $0.35 TO $0.37.EXPECTS TO END 2019 WITH APPROXIMATELY $160 MILLION IN CASH AND MARKETABLE SECURITIES WHICH WILL SUPPORT CURRENT BUSINESS PLAN INTO 2022..

Bleichroeder LP Reports 13.25% Passive Stake In ArQule Inc As Of September 1

Sept 5 (Reuters) - ArQule Inc <ARQL.O>::BLEICHROEDER LP REPORTS 13.25% PASSIVE STAKE IN ARQULE INC AS OF SEPTEMBER 1 - SEC FILING.

Stealth BioTherapeutics Announces Appointment Of Robert Weiskopf As Chief Financial Officer

Sept 3 (Reuters) - Stealth BioTherapeutics Corp <MITO.O>::STEALTH BIOTHERAPEUTICS ANNOUNCES APPOINTMENT OF ROBERT WEISKOPF AS CHIEF FINANCIAL OFFICER.STEALTH BIOTHERAPEUTICS CORP - WEISKOPF MOST RECENTLY SERVED AS CHIEF FINANCIAL OFFICER AND TREASURER FROM 2015 TO 2019..

ArQule Sees FY 2019 Revenue $3.0 Million To $5.0 Million

Aug 7 (Reuters) - ArQule Inc <ARQL.O>::ARQULE REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.08.SEES FY 2019 REVENUE $3.0 MILLION TO $5.0 MILLION.Q2 REVENUE $300,000 VERSUS $13.7 MILLION.Q2 REVENUE ESTIMATE $1 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.09 -- REFINITIV IBES DATA.SEES FY 2019 LOSS PER SHARE $0.35 TO $0.37.NOW EXPECTS TO END 2019 WITH ABOUT $160 MILLION IN CASH AND MARKETABLE SECURITIES WHICH WILL SUPPORT CURRENT BUSINESS PLAN INTO 2022.

ArQule Announces Pricing Of $90 Million Public Offering Of Common Stock

June 25 (Reuters) - ArQule Inc <ARQL.O>::ARQULE ANNOUNCES PRICING OF $90 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.25 MILLION COMMON SHARES PRICED AT $9.75PER SHARE.

Arqule Announces Preliminary Results From Its Phase 1/2 Study Of Miransertib

June 17 (Reuters) - ArQule Inc <ARQL.O>::ARQULE ANNOUNCES PRELIMINARY RESULTS FROM ITS PHASE 1/2 STUDY OF MIRANSERTIB (ARQ 092), IN PATIENTS WITH PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) AND PROTEUS SYNDROME (PS) IN AN ORAL PRESENTATION AT THE EUROPEAN SOCIETY OF HUMAN GENETICS CONFERENCE.ARQULE INC - ENCOURAGING PRELIMINARY SAFETY AND CLINICAL ACTIVITY DATA CONFIRM MIRANSERTIB'S POTENTIAL FOR TREATING PS AND PROS PATIENTS.ARQULE INC - REGISTRATIONAL STUDY, MOSAIC (MIRANSERTIB IN OVERGROWTH SYNDROMES IN ADULTS AND CHILDREN), EXPECTED TO BEGIN ENROLLMENT IN Q3 2019.

Arqule Inc Says Safety Assessment Of Expanded Cohort Was Completed & 65 Mg QD Dose Was Cleared For Safety

March 15 (Reuters) - ArQule Inc <ARQL.O>::ARQULE INC - ON MARCH 7, CO REPORTED THAT ONE PATIENT IN COHORT 7 OF ITS PHASE 1 TRIAL WITH ARQ 531 DOSED AT 65MG QD EXPERIENCED A GRADE 3 RASH.ARQULE INC - FURTHER REPORTED THAT COHORT 7 HAD BEEN EXPANDED PER PROTOCOL, AND THAT TWO ADDITIONAL PATIENTS HAD ALREADY CLEARED 65MG QD DOSE.ARQULE INC - ON MARCH 12, 2019, SAFETY ASSESSMENT OF EXPANDED COHORT WAS COMPLETED, AND 65 MG QD DOSE WAS CLEARED FOR SAFETY.ARQULE INC - NOW INTENDS TO OPEN COHORT 8 AND DOSE PATIENTS AT 75MG QD AS WELL AS DOSE INCREASE EXISTING PATIENTS IN COHORT 6 FROM 45MG TO 65MG QD..

ArQule Says Chief Financial Officer Robert Weiskopf Has Decided To Retire

March 15 (Reuters) - ArQule Inc <ARQL.O>::ARQULE INC - ROBERT WEISKOPF, SENIOR VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER, HAS DECIDED TO RETIRE.ARQULE INC - NAMES MARC SCHEGERIN AS CHIEF FINANCIAL OFFICER.

ArQule Q4 Loss Per Share $0.08

March 7 (Reuters) - ArQule Inc <ARQL.O>::Q4 LOSS PER SHARE $0.08.ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.SEES FY 2019 REVENUE $3.0 MILLION TO $5.0 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.SEES FY 2019 LOSS PER SHARE $0.37 TO $0.39.FY2019 EARNINGS PER SHARE VIEW $-0.34, REVENUE VIEW $5.6 MILLION -- REFINITIV IBES DATA.REVENUES FOR QUARTER ENDED DECEMBER 31, 2018, WERE $2.9 MILLION.ARQULE EXPECTS TO END 2019 WITH BETWEEN $60 AND $63 MILLION IN CASH AND MARKETABLE SECURITIES..

Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

Jan 24 (Reuters) - ArQule Inc <ARQL.O>::BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER.ARQULE INC - ENTERED COLLABORATION WITH ROCHE TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER.ARQULE INC - BASILEA EXPECTS TO START A BIOMARKER-DRIVEN MULTI-COHORT PHASE 1/2 STUDY IN MID-2019..ARQULE INC - BASILEA PHARMACEUTICA ENTERED COLLABORATION WITH ROCHE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up